Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Stud Health Technol Inform ; 217: 659-63, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26294544

RESUMO

Older people with cognitive impairment need support in their everyday living. IN LIFE an EC co-funded project aims to organize large-scale and multi-country pilot applications, by providing interoperable, open, personalised and seamless ICT solutions that support older persons in all key home activities, communication, health maintenance, travel, mobility and socialisation tasks, with novel, scalable and viable business models.


Assuntos
Atividades Cotidianas , Transtornos Cognitivos/reabilitação , Redes de Comunicação de Computadores/organização & administração , Vida Independente , Cuidadores , Comunicação , Humanos , Relações Interpessoais , Autocuidado , Viagem
2.
Br. J. Haematol ; 181(6): 760-769, junio, 2018. tab
Artigo em Inglês | URUCAN | ID: bcc-5205

RESUMO

Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here we report on a new model designed on data from the prospective T Cell Project. Twelve covariates collected by the T Cell Project were analysed and a new model (T cell score), based on four covariates (serum albumin, performance status, stage and absolute neutrophil count) that maintained their prognostic value in multiple Cox proportional hazards regression analysis was proposed. Among patients registered in the T Cell Project, 311 PTCL-NOS were retained for study. At a median follow-up of 46 months, the median overall survival (OS) and progression-free survival (PFS) was 20 and 10 months, respectively. Three groups were identified at low risk (LR, 48 patients, 15%, score 0), intermediate risk (IR, 189 patients, 61%, score 1-2), and high risk (HiR, 74 patients, 24%, score 3-4), having a 3-year OS of 76% [95% confidence interval 61-88], 43% [35-51], and 11% [4-21], respectively (P < 0·001). Comparing the performance of the T cell score on OS to that of each of the previously developed models, it emerged that the new score had the best discriminant power. The new T cell score, based on clinical variables, identifies a group with very unfavourable outcomes(AU)


Assuntos
Humanos , Linfoma de Células T Periférico , Bibliografia Nacional , Uruguai
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA